Polymorphisms of the GSTT1 and GSTM1 genes in polycystic ovary syndrome

INTRODUCTION

Polycystic ovary syndrome (PCOS) is a very common endocrine-metabolic disorder that affects women of reproductive age (18 to 44 years) and one of the main causes of female infertility. Its diagnosis is based on the Rotterdam criteria, that is characterized by the presence of at least two of the following criteria: chronic anovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries,
Genes GSTM1 and GSTT1, located at 1q13.3 and 22q11.2, respectively, belong to the family of GST. Polymorphisms of complete deletion of these genes have already been extensively investigated in type 2 diabetes mellitus (DMT2), a clinical consequence of PCOS. However, only two studies have evaluated the polymorphisms of genes GSTT1 and GSTM1 in PCOS.

Thus, based on the evidence presented, the objective of this study was to investigate the deletion polymorphisms of the genes GSTT1 and GSTM1 in patients with a PCOS and in a control group.

METHODS

The project was approved by the Research Ethics Committee of the Federal University of Triângulo Mineiro (UFTM), under protocol number 1,796, and all participants signed the Informed Consent Form.

The study had the participation of 219 women (110 patients with PCOS and 109 controls), who were being followed-up in the outpatient clinic of General Gynecology, Endocrine Gynecology, and Endocrinology of the Maria da Glória Outpatient Clinic, of...
UFTM, Uberaba, MG, Brasil, at the moment of the study, constituting a sample by convenience. The patients with PCOS were diagnosed with the condition based on the Rotterdam criteria, and the control group was comprised of women of reproductive age, without a history or sign of PCOS. As the exclusion criteria, we did not evaluate patients with Cushing’s syndrome, 21-hydroxylase deficiency, thyroid dysfunction, hyperprolactinemia, diabetes, androgen-secreting tumors, antiandrogens, statins, glucocorticoids, or infertility medications.

We collected 8 mL of peripheral blood, in vacuum tubes with EDTA; the DNA was extracted using the salting-out technique.16

The analysis of the deletion polymorphisms of genes GSTM1 and GSTT1 was carried out using the multiplex PCR technique. The primers for the polymorphism of the gene GSTM1 were sense: 5’ GAA CTC CCT GAA AAG CTA AAG C 3’ and antisense: 5’GTT GGG CTC AAA TAT ACG GTG G 3’ (219 bp) and of gene GSTT1 sense: 5’ TTC CTT ACT GGT CCT CAC ATC TC 3’ and antisense: 5’ TCA CCG GAT CAT GGC CAG CA 3’ (480 bp). The sequence of primers for gene CYP1A1 was sense: 5’ GAA CTG CCA CTT CAG CTG TCT 3’ and antisense: 5’ CAT GGG CCA GCG CAT GTA GCT 3’ (312 bp), and this gene was used as an internal positive control for the reaction.

The PCR reaction was carried out on a final volume of 30 μl, containing 0.2 mM dNTP, 1x PCR buffer, 3 pmol of each primer, 1 unit of Taq DNA Polymerase, and approximately 100 ng of genomic DNA. The PCR amplification consisted of an initial stage at 94 °C for 5 minutes, followed by 35 cycles at 94 °C for 2 minutes (denaturation), 59 °C for 1 minute (annealing), 72 °C for 1 minute (extension), and a final extension at 72 °C for 10 minutes. The PCR products were applied in 1.5% agarose gel, stained using GelRed™, and analyzed under ultraviolet light for genotyping.

We used the chi-square test to compare data from the case and control groups. The multiple logistic regression model was used to determine the effects of risk factors (smoking, family history of PCOS, alcoholism, and presence of polymorphisms) in PCOS. The results of the logistic regression analysis were presented in odds-ratio (OR) and with a confidence interval of 95% (95% CI). For all analyzes, the level of significance was set at 5% (p≤0.05).

**RESULTS**

The mean age of the patients and the control group was 26 years (±7.54) and 31 years (±9.25), respectively. Regarding the risk factors, the data show that 13.8% of the participants are smokers, something that was more frequent in the control group. With regard to alcoholism, it was observed that 27.8% of the women studied had this habit, but no significant differences were found between the groups. Observing the family history of PCOS, 29.3% of the participants had relatives with PCOS, with a significant difference between the groups, and the patients had a greater number of relatives with PCOS (67.6%) compared to the control group (32.4%).

In Table 1 it is possible to see the frequency of the deletion polymorphisms of genes GSTT1 and GSTM1 in women with PCOS and in the control group. No significant differences were observed between the groups when they were analyzed individually.

The analysis of the combined genotypes showed differences between the group of patients and the controls ($\chi^2=11.534, p=0.005$) (Table 2). This analysis shows that the combination of genotypes GSTT1 +/GSTM1- is more frequent in patients.

The multivariate analysis carried out to determine

**TABLE 2. FREQUENCY OF THE GENOTYPES GSTT1 AND GSTM1 COMBINED IN PATIENTS WITH PCOS AND CONTROLS.**

| Genotypes         | Patient n (%) | Control n (%) | P   |
|-------------------|---------------|---------------|-----|
| GSTT1+/GSTM1+     | 44 (40)       | 52 (47.7)     | <0.05|
| GSTT1+/GSTM1-     | 38 (34.5)     | 17 (15.6)     |     |
| GSTT1-/GSTM1+     | 16 (14.5)     | 27 (24.8)     |     |
| GSTT1-/GSTM1-     | 12 (10.9)     | 13 (11.9)     |     |

Note: Values of P ≤0.05 are significant; [+]: Presence of the gene; [-]: Deletion of the gene.
the effects of risk factors (smoking, family history of PCOS, alcoholism, and presence of polymorphisms) in PCOS showed that smokers were more frequent in the control group (odds ratio=0.22; CI 95% - 0.87-0.57; p=0.002), while a family history of PCOS (OR=2.96; 95% CI: 1.54-5.68; p=0.001) was more frequent among women with the syndrome, with a significant difference between the groups. The variables of alcoholism and deletion polymorphisms of genes GSTT1 and GSTM1 presented no statistically significant differences between the groups analyzed.

**DISCUSSION**

Glutathione S-transferases (GSTs) are a superfamily of detoxifying enzymes involved in maintaining cellular integrity, oxidative stress, and protection against DNA damage. Many polymorphisms have been reported to occur in GST coding genes, which can reduce their efficiency and increase the risk of certain human diseases, such as cancer.

A study explored the association between PCOS and oxidative stress and examined the relationship between biomarkers of oxidative stress and insulin parameters, concluding that oxidative stress may be a contributing factor for future risk of cardiovascular disease in these women, in addition to known characteristics such as dyslipidemia and obesity. Besides obesity, there is evidence that sex hormones, particularly estradiol, in PCOS can contribute to increased oxidative stress.

In the present study, no association was found between the deletion of genes GSTT1 and GSTM1 and PCOS in isolation, only in combination. A previous study suggests that the combined effect of CYP1A1 and the mutant genotypes GSTM1 and GSTT1 confers an increased risk of the syndrome in Indian women. Another study analyzed parameters of oxidative stress and GST polymorphisms in non-obese adolescents, with normal levels of insulin, and recently diagnosed with PCOS. Regarding the molecular data, girls with PCOS, carriers of the null GSTM1 genotype showed significantly lower testosterone in comparison with those carriers of the active GSTM1 genotype.

Another study investigated the four most common polymorphisms of GST (GSTM1, T1, A1, and P1) in epithelial ovarian cancer and found that these can affect both the susceptibility to and the progression of this type of cancer.

Polymorphisms in genes GSTT1 and GSTM1 were analyzed in gynecological conditions such as endometriosis and pre-eclampsia, with divergent results (Table 3), even in populations of the same country of origin. The discrepancy between the results may be due to the particularities of the samples investigated in regarding their ethnicity and genetic background. It is also important to highlight that, in addition to PCOS, endometriosis is one of the main causes of female infertility.

DMT2 is highly prevalent in patients with PCOS.

| Study/Country of origin | Sample | Association |
|-------------------------|--------|-------------|
| Henidi et al./Tunisia | 105 women with endometriosis | Yes |
| Kubiszieski et al./Brasil | 121 women with endometriosis | No - GSTM1 Yes - GSTT1 |
| Tuo et al./China | 262 women with endometriosis | No |
| Batista et al./Brasil | 49 women with endometriosis | No |
| Guan et al./China | 232 women with pre-eclampsia | Yes |
| Slijivanacink Jakovljevic et al./Serbia | 50 women with pre-eclampsia | Yes |

Seven studies investigated the polymorphisms in the genes GSTT1 and GSTM1 in patients with DMT2 and positively associated them with the condition, either individually or in combination. One of these studies was carried out with 120 Brazilian patients with DMT2 and it suggests that the null GSTM1 and GSTT1 genotypes may contribute to the clinical course of the disease. A meta-analysis of 25 studies concluded that the null GSTM1 and GSTT1 genotypes increase the risk of DMT2 alone, in combination, or with respect to ethnicity.

In this study, the multiple logistic regression model showed an increased frequency of smokers in the control group, which may be a peculiar characteristic of the sample. The increased frequency of PCOS in the study group is associated with the multifactorial nature of the condition, which demonstrates the contribution of genetic factors in its etiology.

Recently, a multicenter study was published in Brasil that could guide public strategies specific for primary and secondary prevention of metabolic and reproductive comorbidities in the population with...
PCOS in the country. This information is extremely relevant in view of the extension of our country associated with a population of mixed ethnic origin and marked variation of diet and cultural characteristics. These characteristics provide a unique opportunity to investigate the association of factors related to lifestyle, environment, genetics, epigenetics, and the phenotypic expression of PCOS.

One limitation of our study was the sample analyzed, considered small for research with genetic polymorphisms. However, the scarcity of studies published on polymorphisms in the genes GSTM1 and GSTT1 in PCOS compromised the comparison with the results found herein but emphasizes the need for additional studies regarding the contribution of these polymorphisms to the development of this endocrinopathy.

It is also important to highlight that the lack of association in our study may be due to the ethnicity and genetic background of the population investigated. Another interesting approach, in subsequent studies, would be to examine whether there is an association between comorbidities such as DMT2, central obesity, and cardiovascular disease and the polymorphisms analyzed. However, this would require dividing the patients into subgroups, which might not have statistical significance.

It is also worth mentioning that there are environmental, behavioral, and psychological factors that can interfere with the phenotype of PCOS, and that the sample does not reflect the community, since they were patients who sought care. Therefore, further studies are needed in order to minimize this sample bias. Thus, the lack of association of the gene polymorphisms studied and the syndrome should also be explored.

CONCLUSIONS

The deletion polymorphisms of genes GSTT1 and GSTM1 in isolation are not associated with PCOS; however, in combination, they may be involved in the etiology of the condition in the sample investigated.

Financial Aid

Fundação de Amparo à Pesquisa do Estado de Minas Gerais (Fapemig) (APQ 01608-14) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Process 476423/2013-9).

Author’s Contribution

Mariana Mendes Porto Azevedo, Alessandra Bernardete Trovó de Marqui: concept, data collection and analysis, writing; Bruna Tavares Bacalá, Marly Aparecida Spadotto Balarin, Marco Fábio Prata Lima, Mariana Kefalas Oliveira Gomes, Elisabete Aparecida Mantovani Rodrigues de Resende: data collection and analysis. Mariangela Torreglosa Ruiz Cintra: project design, data collection and analysis, article writing. All authors participated in the final analysis of the article.
REFERENCES

1. Ajmal N, Khan SZ, Shaffer R. Polycystic ovary syndrome (PCOS) and genetic predisposition: a review article. Eur J Obstet Gynecol Reprod Biol. 2019;3:10060.

2. Sulaiman MA, Al-Farsi YM, Al-Khaduri MM, Saleh J, Waly MI. Polycystic ovarian syndrome is linked to increased oxidative stress in Omani women. Int J Womens Health. 2018;10:763-71.

3. Mohammadi M. Oxidative stress and polycystic ovary syndrome: a brief review. Int J Prev Med. 2019;10:86.

4. Chatterjee A, Gupta S. The multifaceted role of glutathione S-transferases in cancer. Cancer Lett. 2018;433:33-42.

5. Pearson WR, Vorachek WR, Xu SJ, Berger R, Hart I, Vannais D, et al. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet. 1993;53(1):220-33.

6. Webb G, Vaska V, Coggan M, Board P. Chromosomal localization of the gene for the human theta class glutathione transferase (GSTT1). Genomics. 1996;33(1):121-3.

7. Ameer MA, Ghatts MH, Abo-Elmatty DM, Abou-EI-Ela SH. Influence of glutathione S-transferase polymorphisms on type-2 diabetes mellitus risk. Genet Mol Res. 2011;10(4):3722-30.

8. Gönül N, Kadioglu E, Kocabaş NA, Ozkaya M, Karakaya AE, Karahalil B. The role of GSTM1, GSTT1, GSTP1, and DGG1 polymorphisms in type 2 diabetes mellitus risk: a case-control study in a Turkish population. Gene. 2012;505(1):121-7.

9. Moasser E, Kazemi-Nezhad SR, Saadat M, Arzpira N. Study of the association between glutathione S-transferase (GSTM1, GSTT1, GSTP1) polymorphisms with type II diabetes mellitus in southern of Iran. Mol Biol Rep. 2012;39(12):10187-92.

10. Pinheiro DS, Rocha Filho CR, Mundim CA, Marco P Jr, Ulhoa CJ, Reis AAS, et al. Evaluation of glutathione S-transferase GSTM1 and GSTT1 deletion polymorphisms on type-2 diabetes mellitus risk. PLoS One. 2013;8(10):e76262.

11. Raza S, Abbas S, Ahmad A, Ahmed F, Zaidi ZH, Mahdi F. Association of glutathione-S-transferase (GSTM1 and GSTT1) and FTO gene polymorphisms with type-2 diabetes mellitus cases in northern India. Balkan J Med Genet. 2014;17(1):47-54.

12. Pororan MD, Bala C, Ilies R, Catana A, Popp RA, Dumitrascu DL. Combined glutathione S transferase M1/T1 null genotypes is associated with type 2 diabetes mellitus. Clujul Med. 2015;88(2):159-63.

13. Azarová I, Bushueva O, Konoplyva A, Polonikov A. Glutathione S-transferase genes and the risk of type 2 diabetes mellitus: role of sexual dimorphism, gene-gene and gene-smoking interactions in disease susceptibility. J Diabetes. 2018;10(5):389-407.

14. Babu KA, Rao KL, Kanakavalli MK, Suryanarayana VV, Deenadayal M, Singh L. CYPIA1, GSTM1 and GSTT1 genetic polymorphism is associated with susceptibility to polycystic ovaries in South Indian women. Reprod Biomed Online. 2004;9(2):194-200.

15. Savić-Radojević A, Mažibrada I, Đukić T, Stanković ZB, Pjetla-Encegovac M, Sedlecý K, et al. Glutathione S-transferase (GST) polymorphism could be an early marker in the development of polycystic ovary syndrome (PCOS): an insight from non-obese and non-insulin resistant adolescents. Endokrynol Pol. 2018;69(4):366-74.

16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.

17. Fatima Q, Amin S, Kawa IA, Jeliai H, Manzoor S, Rizvi SM, et al. Evaluation of antioxidant defense markers in relation to hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): a case-control study. Diabetes Metab Syndr. 2019;13(3):1957-61.

18. Pljesa I, Berisavac M, Simic T, Pelemezovic T, Coric V, Suvakov S, et al. Polymorphic expression of glutathione transferases A1, M1, P1 and T1 in epithelial ovarian cancer: a Serbian case-control study. J Buon. 2017;22(1):72-9.

19. Henidi B, Kaaebachi S, Mrbarik M, Zhoua A, Hamzaoui K. Glutathione S-transferase M1 and T1 gene polymorphisms and risk of endometriosis in Tunisian population. Hum Fertil (Camb). 2015;18(2):128-33.

20. Kubiszewski EH, Medeiros SF, Silva Sedel JA, Barbosa JS, Galera BB. Glutathione S-transferase M1 and T1 gene polymorphisms in Brazilian women with endometriosis. J Assist Reprod Genet. 2015;32(10):1521-5.

21. Tuo Y, He Y, Yan WJ, Yang J. Association between CYP19A1, GSTM1, GSTT1, and GSTP1 genetic polymorphisms and the development of endometriosis in a Chinese population. Genet Mol Res. 2016;15(4).

22. Batista LC, Ruiz-Cintra MT, Lima MMP, Marqui ABT. No association between glutathione S-transferase M1 and T1 gene polymorphisms and susceptibility to endometriosis. J Bras Patol Med Lab. 2017;53(3):183-7.

23. Guan L, Fan P, Liu X, Liu R, Chen Y, Ye L, et al. Association study between GSTT1 and GSTM1 polymorphisms and risk of preeclampsia in Chinese population. Eur J Obstet Gynecol Reprod Biol. 2016;204:31-5.

24. Slivancanin Jakovljevic T, Kontic-Vucinic O, Nikolic N, Caric J, Soldatovic I, Milasin J. Glutathione S–transferase M1 polymorphism and pro-inflammatory cytokines tumour necrosis factor-α and interleukin-1ß are associated with preeclampsia in Serbian women. Am J Reprod Immunol. 2019;81(5):e13105.

25. Lazaridou S, Onias K, Tzironalos K. Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome. Hormones (Athens). 2017;16(4):373-80.

26. Nazir S, Sab S, Bhownik S, Ghosh SK, Choudhury Y. The GSTM1 and GSTT1 null genotypes increase the risk for type 2 diabetes mellitus and the subsequent development of diabetic complications: a meta-analysis. Curr Diabetes Rev. 2019;15(1):31-43.

27. Spritzer PM, Marchesan LB, Santos BR, Cureu-FV, Oppermann K, Reis RM, et al. Prevalence and characteristics of polycystic ovary syndrome in Brazilian women: protocol for a nation-wide case-control study. BMJ Open. 2019;9(10):e029191.

28. Soares Junior M, Barurat MC, Maciel GA, Barurat EC. Polycystic ovary syndrome: controversies and challenges. Rev Assoc Med Bras. 2015;61(6):485-7.